Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496)

By  

CANCER, Vol. 122, Iss. 19, 2016-10 ,pp. : 2996-3004

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 328-335

Karger

Access to resources Recommend Favorite

Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 1, 2015-07 ,pp. : 56-65

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 6, 2015-09 ,pp. : 1397-1405

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

By  

Oncology, Vol. 82, Iss. 5, 2012-04 ,pp. : 290-297

Karger

Access to resources Recommend Favorite